Results 31 to 40 of about 215,802 (313)

TORC1 coordinates the conversion of Sic1 from a target to an inhibitor of cyclin-CDK-Cks1 [PDF]

, 2017
Eukaryotic cell cycle progression through G1–S is driven by hormonal and growth- related signals that are transmitted by the target of rapamycin complex 1 (TORC1) pathway.
Jaquenoud, Malika, Moreno-Torres, Marta, Nicastro, Raffaele, Péli-Gulli, Marie-Pierre, Virgilio, Claudio De   +4 more
core   +2 more sources

Identification of calpain cleavage sites in the G1 cyclin-dependent kinase inhibitor p19(INK4d) [PDF]

, 2006
Calpains are a large family of Ca2+-dependent cysteine proteases that are ubiquitously distributed across most cell types and vertebrate species. Calpains play a role in cell differentiation, apoptosis, cytoskeletal remodeling, signal transduction and ...
Croall, Dayton, Fischer, Fuchs, Goll, Harris, Inomata, Kuboki, Lee, Molinari, Nicotera, Ruas, Sasaki, Smialowski   +13 more
core   +2 more sources

Anexelekto/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms

Haematologica, 2017
Nearly one-third of patients with acute myeloid leukemia have FMS-like tyrosine kinase 3 mutations and thus have poor survival prospects. Receptor tyrosine kinase anexelekto is critical for FMS-like tyrosine kinase 3 signaling and participates in FMS ...
Peter P. Ruvolo, Huaxian Ma, Vivian R. Ruvolo, Xiaorui Zhang, Hong Mu, Wendy Schober, Ivonne Hernandez, Miguel Gallardo, Joseph D. Khoury, Jorge Cortes, Michael Andreeff, Sean M. Post   +11 more
doaj   +1 more source

Modulation of plant growth in vivo and identification of kinase substrates using an analog-sensitive variant of CYCLIN-DEPENDENT KINASE A;1 [PDF]

, 2016
BACKGROUND: Modulation of protein activity by phosphorylation through kinases and subsequent de-phosphorylation by phosphatases is one of the most prominent cellular control mechanisms.
Dissmeyer, N., Hammann, P., Harashima, H., Kramer, K., Nakagami, H., Nomura, Y., Schnittger, A.   +6 more
core   +2 more sources

The Role of p27kip1 in the Aggressiveness of Papillary Thyroid Carcinoma: A Clinicopathological Analysis

مجلة كلية الطب
Background: Cell-cycle-regulating proteins, including cyclin-dependent kinase inhibitor 1B p27kip1, have been researched in different malignancies, including thyroid carcinoma, and their association with tumor aggressiveness and recurrence has been ...
Wafaa K. Ibrahim, khitam R. Al-khafaji
doaj   +1 more source

Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo [PDF]

, 2018
Lenvatinib is an oral, multitargeted tyrosine kinase inhibitor (TKI) of VEGFR1-VEGFR3, FGFR1-FGFR4, PDGFRα, RET and v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) signaling networks involved in tumor angiogenesis.
Antonelli, Alessandro, Baldini, Enke, Bocci, Guido, Di Desidero, Teresa, Elia, Giusy, Fallahi, Poupak, Ferrari, Silvia Martina, Materazzi, Gabriele, Miccoli, Paolo, Motta, Concettina La, Orlandi, Paola, Paparo, Sabrina Rosaria, Patrizio, Armando, Piaggi, Simona, Ragusa, Francesca, Ruffilli, Ilaria, Ulisse, Salvatore   +16 more
core   +2 more sources

Deletion of cyclin dependent kinase inhibitor 2a gene as a marker of oropharyngeal carcinomas non-associated with human papillomavirus and its prognostic value

Medičnì Perspektivi
Patients with human papilloma virus associated oropharyngeal squamous cell carcinoma generally have better treatment outcomes and prognosis compared to those with non-papillomavirus-associated oropharyngeal squamous cell carcinoma.
I.S. Shponka, O.O. Bondarenko, O.V. Kovtunenko, V.V. Rakhmanov   +3 more
doaj   +1 more source

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. [PDF]

, 2017
Background: CDK 4 and 6 inhibitors (CDK4/6i), which arrest unregulated cancer cell proliferation, show clinical efficacy in breast cancer. Unexpectedly, a patient treated on a CDK4/6i-based trial, as first-line therapy in metastatic breast cancer ...
Abouharb, Sausan, Bashour, Sami I, Brown, Powel H, Doostan, Iman, Ibrahim, Nuhad K, Karuturi, Meghan, Keyomarsi, Khandan, Koenig, Kimberly B, Litton, Jennifer K, Moulder-Thompson, Stacy L, Tripathy, Debasish, Ueno, Naoto T, Valero, Vicente   +12 more
core   +2 more sources

Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma

Journal of Experimental & Clinical Cancer Research, 2018
Background Patient-derived xenograft (PDX) tumor model has become a new approach in identifying druggable tumor mutations, screening and evaluating personalized cancer drugs based on the mutated targets.
Cheng-Lung Hsu, Kar-Wai Lui, Lang-Ming Chi, Yung-Chia Kuo, Yin-Kai Chao, Chun-Nan Yeh, Li-Yu Lee, Yenlin Huang, Tung-Liang Lin, Mei-Yuan Huang, Yi-Ru Lai, Yuan-Ming Yeh, Hsien-Chi Fan, An-Chi Lin, Yen-Jung Lu, Chia-Hsun Hsieh, Kai-Ping Chang, Ngan-Ming Tsang, Hung-Ming Wang, Alex Y. Chang, Yu-Sun Chang, Hsin-Pai Li   +21 more
doaj   +1 more source

Cell Cycle Control by Xenopus p28^(Kix1) a Developmentally Regulated Inhibitor of Cyclin-dependent Kinases [PDF]

, 1996
We have isolated Xenopus p28^(Kix1), a member of the p21^(CIP1)/p27^(KIP1)/p57^(KIP2) family of cyclin-dependent kinase (Cdk) inhibitors. Members of this family negatively regulate cell cycle progression in mammalian cells by inhibiting the activities of
Dunphy, William G., Shou, Wenying
core